SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.4B
Q3 2019
Positions
49
Filings on Record
27
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Boxer Capital, LLC reported $1.4B in U.S.-listed holdings across 49 positions for Q3 2019.

Its largest position, ONCEEUR, represents 11.6% of the portfolio.

Compared with Q2 2019, the fund opened 13 new positions and exited 1.

Portfolio Metrics

Turnover
+16.0%
vs prior filed quarter
Top-10 Concentration
+59.8%
share of reported value
Largest Position
+11.6%
Spark Therapeutics
New / Exited
13 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.0%Other: 23.1%ADR: 9.9%
  • Common Stock · 67.0% · $924M
  • Other · 23.1% · $319M
  • ADR · 9.9% · $136M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AMARIN CORP PLCNEW+3.50M3.50M+$53M$53M
SWTXUSDSPRINGWORKS THERAPEUTICS INCNEW+2.08M2.08M+$45M$45M
SRPTSAREPTA THERAPEUTICS INCNEW+550.0K550.0K+$41M$41M
BMRNBIOMARIN PHARMACEUTICAL INCNEW+450.0K450.0K+$30M$30M
APLSUSDAPELLIS PHARMACEUTICALS INCNEW+700.0K700.0K+$17M$17M
ZGNXEURZOGENIX INCNEW+300.0K300.0K+$12M$12M
BLUBELLUS HEALTH INC NEWNEW+1.77M1.77M+$11M$11M
AVROBIO INCNEW+600.0K600.0K+$8M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ONCEEURSPARK THERAPEUTICS INChistory →COM11.60%$160M1.65M
2MRTXEURMIRATI THERAPEUTICS INChistory →COM9.69%$134M1.72M
3ONCBEIGENE LTDhistory →SPONSORED ADR8.21%$113M925.0K
4IMMUIMMUNOMEDICS INChistory →COM6.68%$92M6.95M
5ODONATE THERAPEUTICS INCCOM6.35%$88M3.36M
6ALLKGUSDALLAKOS INChistory →COM3.85%$53M675.0K
7AMARIN CORP PLCSPONS ADR NEW3.85%$53M3.50M
8DBV TECHNOLOGIES S ASPONSORED ADR3.30%$46M5.30M
9SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM3.26%$45M2.08M
10SRPTSAREPTA THERAPEUTICS INChistory →COM3.00%$41M550.0K
11SOLID BIOSCIENCES INCCOM2.92%$40M3.90M
12MDCOUSDMEDICINES COhistory →COM2.72%$38M750.0K
13ESPRESPERION THERAPEUTICS INC NEhistory →COM2.59%$36M975.0K
14GOSSGOSSAMER BIO INChistory →COM2.53%$35M2.08M
15UNIQURE NVSHS2.47%$34M865.4K
16PTCTPTC THERAPEUTICS INChistory →COM2.45%$34M1.00M
17BMRNBIOMARIN PHARMACEUTICAL INChistory →COM2.20%$30M450.0K
18ARGXARGENX SEhistory →SPONSORED ADR1.65%$23M200.0K
19ATRECA INCCL A COM1.54%$21M1.73M
20MISTMILESTONE PHARMACEUTICALS INhistory →COM1.49%$21M1.10M
21WAVE LIFE SCIENCES LTDSHS1.49%$21M1.00M
22AM6AMICUS THERAPEUTICS INChistory →COM1.35%$19M2.33M
23RCKTROCKET PHARMACEUTICALS INChistory →COM1.24%$17M1.47M
24APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.22%$17M700.0K
25PREVAIL THERAPEUTICS INCCOM1.00%$14M1.12M
26KURAKURA ONCOLOGY INChistory →COM0.93%$13M844.8K
27GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM0.88%$12M250.0K
28ZGNXEURZOGENIX INChistory →COM NEW0.87%$12M300.0K
29BLUBELLUS HEALTH INC NEWhistory →COM NEW0.82%$11M1.77M
30AKROAKERO THERAPEUTICS INChistory →COM0.80%$11M482.5K
31KDMNKADMON HLDGS INChistory →COM0.73%$10M4.00M
32VYGRVOYAGER THERAPEUTICS INCCOM0.62%$9M500.0K
33AVROBIO INCCOM0.61%$8M600.0K
34LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.55%$8M2.50M
35ACHNEURACHILLION PHARMACEUTICALS INCOM0.52%$7M2.00M
36IDYAIDEAYA BIOSCIENCES INCCOM0.50%$7M764.3K
37LJPCLA JOLLA PHARMACEUTICAL COCOM PAR $.0001 20.49%$7M775.0K
38MTNBEURMATINAS BIOPHARMA HLDGS INCCOM0.47%$6M10.19M
39CYMABAY THERAPEUTICS INCCOM0.46%$6M1.25M
40MEI PHARMA INCCOM NEW0.35%$5M2.91M
41SNDXSYNDAX PHARMACEUTICALS INCCOM0.22%$3M400.0K
42RCUSARCUS BIOSCIENCES INCCOM0.20%$3M300.0K
43MERSANA THERAPEUTICS INC.COM0.19%$3M1.68M
44KINIKSA PHARMACEUTICALS LTDCOM CL A0.18%$2M290.6K
454XC1KALVISTA PHARMACEUTICALS INCCOM0.17%$2M200.0K
46CELLECTAR BIOSCIENCES INCCOM PAR0.13%$2M920.0K
47PROTHENA CORP PLCSHS0.05%$624,00079.6K
48TKAIEURNOVUS THERAPEUTICS INCCOM0.01%$201,000324.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.